Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Multiscale Model Identifies Improved Schedule for Treatment of Acute Myeloid Leukemia In Vitro With the Mcl‐1 Inhibitor AZD5991

CPT Pharmacometrics & Systems Pharmacology(2020)10.1002/psp4.12552Source: DataRank Database

Multiscale Model Identifies Improved Schedule for Treatment of Acute Myeloid Leukemia In Vitro With the Mcl‐1 Inhibitor AZD5991 is a research paper published in CPT Pharmacometrics & Systems Pharmacology (2020). On theSindex it has a DataRank of 0. It has been cited 3 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access3 citations

Download PDF

Cite:

Linked data & code

doi

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (3 grants)Impact (FWCI 0.23)OA: goldTopics (45)IDs (PubMed, PMC, OpenAlex)Annotations (1)SDGs (2)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (10)

Haley Woods,Adriana E. Tron ORCID,Matthew A. Belmonte,J. Paul Secrist ORCID,Douglas Ferguson

Live enrichment

PubMed:32860732 PMC:PMC7577016 OpenAlex:https://openalex.org/W3082863124

NLM NIH HHS

Grant: DP2 LM011952

NIH HHS

Grant: 1DP2LM011952

National Institutes of Health

Grant: 1DP2LM011952-01

Quantitative Design of Multi-drug Regiments for Tuberculosis

FWCI

0.23

Citation Percentile

0.5%

Citation Trend

2021

2023

2024

goldLicense: cc-by-nc-nd

journalhttps://ascpt.onlinelibrary.wiley.com/doi/pdfdirect/10.1002/psp4.12552

publisherhttps://ascpt.onlinelibrary.wiley.com/doi/pdfdirect/10.1002/psp4.12552

publisherhttps://onlinelibrary.wiley.com/doi/pdf/10.1002/psp4.12552

publisherhttps://onlinelibrary.wiley.com/doi/full-xml/10.1002/psp4.12552

publisherhttps://ascpt.onlinelibrary.wiley.com/doi/pdf/10.1002/psp4.12552

Fields of Study

Chronic Myeloid Leukemia TreatmentsCytokine Signaling Pathways and InteractionsAcute Myeloid Leukemia Research0301 basic medicine03 medical and health sciences

MeSH Terms

AnimalsAntineoplastic AgentsDrug Administration ScheduleHumansLeukemia, Myeloid, AcuteApoptosisDrug Resistance, NeoplasmXenograft Model Antitumor AssaysModels, AnimalCell Line, TumorMacrocyclic CompoundsMiceMyeloid Cell Leukemia Sequence 1 Protein

Keywords

Myeloid leukemiaIn vitroSchedulePharmacologyMyeloidCancer researchMedicineOncologyChemistryComputer scienceBiochemistryMacrocyclic CompoundsResearchAntineoplastic AgentsApoptosisRM1-950Xenograft Model Antitumor AssaysDrug Administration ScheduleLeukemia, Myeloid, AcuteMiceDrug Resistance, NeoplasmCell Line, TumorModels, AnimalAnimalsHumansMyeloid Cell Leukemia Sequence 1 ProteinTherapeutics. Pharmacology

Sustainable Development Goals

SDG 3: 3. Good healthSDG 0: Good health and well-being